Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 21 for:    fenugreek

A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03272295
Recruitment Status : Not yet recruiting
First Posted : September 5, 2017
Last Update Posted : September 5, 2017
Sponsor:
Collaborators:
Philip Morris Products S.A.
Imperial Tobacco Group PLC
Japan Tobacco Inc.
Korea Ginseng Corporation
Information provided by (Responsible Party):
British American Tobacco (Investments) Limited

Brief Summary:
This study will compare nicotine delivery and smoking behaviour in healthy subjects using several combustible cigarette prototypes containing different ingredients which are commonly used in the European Union.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Smoking Other: Reference cigarette Other: Cigarette with carob bean extract Other: Cigarette with cocoa powder Other: Cigarette with fenugreek extract Other: Cigarette with fig juice Other: Cigarette with glycerol Other: Cigarette with guaiacol Other: Cigarette with liquorice extract powder Other: Cigarette plus I-menthol Other: Cigarette with propylene glycol Other: Cigarette with sorbitol Other: Cigarette with multiple ingredients Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Masking Description: A double-blind study in respect of the site (except pharmacy) and subjects.
Primary Purpose: Other
Official Title: A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients
Estimated Study Start Date : September 12, 2017
Estimated Primary Completion Date : December 1, 2017
Estimated Study Completion Date : December 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Experimental: Arm A
Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
Other: Reference cigarette
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.

Other: Cigarette with carob bean extract
Based on reference cigarette with added ingredient

Other: Cigarette with cocoa powder
Based on reference cigarette with added ingredient

Other: Cigarette with fenugreek extract
Based on reference cigarette with added ingredient

Other: Cigarette with fig juice
Based on reference cigarette with added ingredient

Other: Cigarette with glycerol
Based on reference cigarette with added ingredient

Other: Cigarette with multiple ingredients
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.

Experimental: Arm B
Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
Other: Reference cigarette
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.

Other: Cigarette with guaiacol
Based on reference cigarette with added ingredient

Other: Cigarette with liquorice extract powder
Based on reference cigarette with added ingredient

Other: Cigarette plus I-menthol
Based on reference cigarette with added ingredient

Other: Cigarette with propylene glycol
Based on reference cigarette with added ingredient

Other: Cigarette with sorbitol
Based on reference cigarette with added ingredient

Other: Cigarette with multiple ingredients
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.




Primary Outcome Measures :
  1. Cmax [ Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff ]
    To assess the maximum nicotine concentration when subjects smoke a single cigarette


Secondary Outcome Measures :
  1. AUC0-last [ Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff ]
    To assess the area under the concentration curve from time 0 to last the time-point when subjects smoke a single cigarette

  2. Tmax [ Time Frame: -5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 60, 120, 180 and 240 minutes in relation to the first puff ]
    To assess the time to maximum nicotine concentration when subjects smoke a single cigarette

  3. Puff Volume [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess puff volume when subjects smoke a single cigarette

  4. Puff duration [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess puff duration when subjects smoke a single cigarette

  5. Number of puffs [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess number of puffs when subjects smoke a single cigarette

  6. Inhalation volume [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess inhalation volume when subjects smoke a single cigarette

  7. Exhalation volume [ Time Frame: During the time required to smoke a single cigarette (up to 8 minutes) ]
    To assess exhalation volume when subjects smoke a single cigarette



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subjects will be:

    1.1. males or females 1.2. 21 to 55 years of age, inclusive, demonstrated by appropriate proof of identification.

  2. Subjects will have a:

    2.1. BMI of 18.5 to 30.0 kg/m2, inclusive 2.2. body weight exceeding 52 kg (males) or 45 kg (females)

  3. Subjects will be in good health, as judged by the PI or the appropriately qualified designee based on:

    3.1. medical history 3.2. physical examination 3.3. vital signs assessment 3.4. 12-lead ECG 3.5. clinical laboratory evaluations 3.6. lung function tests

  4. Subjects will have given their written informed consent to participate in the study and will have agreed to abide by the study restrictions.
  5. Subjects must demonstrate the ability to comprehend the informed consent form (ICF), be able to communicate well with the PI or the appropriately qualified designee, understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the PI or the appropriately qualified designee.
  6. Subjects will be willing to refrain from consuming alcohol within 24 hours prior to Admission.
  7. Subjects will be regular smokers of factory made, non-menthol cigarettes whose chosen brand is within the ISO tar bands 6 to 10 mg, inclusive and should not change their usual brand cigarette for the duration of the study.
  8. Subjects will have smoked their chosen brand for a minimum of 6 months and will have smoked for at least 3 years prior to Screening, and will typically smoke at least 10 and a maximum of 30 CPD.
  9. Subjects must have a urine cotinine level >200 ng/mL and an ECO measurement of >10 ppm at Screening.
  10. Subjects will be willing to use the study products and smoke only the study products provided to them during clinical confinement and to abstain from smoking when required.

Exclusion Criteria:

  1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use a barrier method of contraception (i.e., a condom with spermicide) in addition to a second highly effective method of contraception used by their female partners or to refrain from donating sperm from Admission for Visit 1 until 5-7 days after Discharge.
  2. Female subjects of childbearing potential who do not agree to use a highly effective method of birth control in conjunction with male barrier method contraception (i.e., a condom with spermicide) from the time of signing the ICF until 5-7 days after Discharge.
  3. Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and at each Admission. Any female subject who becomes pregnant during this study will be withdrawn.
  4. Subjects who have donated:

    4.1. ≥450 mL of blood within 90 days prior to Admission 4.2. plasma in the 7 days prior to Admission 4.3. platelets in the 6 weeks prior to Admission

  5. Subjects who have an acute illness (e.g., upper respiratory tract infection, viral infection, etc.) requiring treatment within 4 weeks prior to Admission.
  6. Subjects who have used any nicotine or tobacco product other than commercially manufactured non-menthol, filter cigarettes within 14 days of Screening.
  7. Subjects who are self-reported non-inhalers (smokers who draw smoke from the cigarette into the mouth and throat but who do not inhale). Subjects who are determined as non-inhalers at Screening will be excluded.
  8. Subjects who, prior to enrolment, are planning to quit smoking in the next 12 months of Screening. All subjects will be informed that they are free to quit smoking and withdraw from the study at any time. Any subject who decides to quit smoking will be directed to appropriate stop smoking services
  9. Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the PI or the appropriately qualified designee.
  10. Subjects who have a positive urine drugs of abuse or alcohol screen (confirmed by repeat) at Screening or Admission.
  11. Subjects who:

    11.1. have serum hepatitis 11.2. are carriers of the hepatitis B surface antigen (HBsAg) 11.3. are carriers of the hepatitis C antibody 11.4. have a positive result for the test for human immunodeficiency virus (HIV) antibodies.

  12. Subjects who have used prescription or OTC bronchodilator medication (e.g., inhaled or oral β-adrenergic agonists) to treat a chronic condition within the 12 months prior to the first Admission (Visit 1) and throughout the study.
  13. Subjects who have received any medications or substances (other than tobacco) which:

    13.1. are known to be strong inducers or inhibitors of CYP enzymes within 14 days or 5 half-lives of the drug (whichever is longer) prior to the first Admission (Visit 1) and throughout the study.

  14. Subjects who are planning to undergo significant lifestyle changes during the study e.g., big change in exercise levels.
  15. Subjects who are unable to communicate effectively with the PI/study staff (i.e., language problem, poor mental development, or impaired cerebral function).
  16. Subjects who are unwilling or unable to comply with the study requirements.
  17. Employees, and immediate relatives, of the tobacco industry or the clinical site.
  18. Subjects who are still participating in another clinical study (e.g., attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first Admission (Visit 1).
  19. Subjects who have any clinically relevant abnormal findings on the physical examination, medical history, ECG, lung function tests (forced expiratory volume in 1 second/ forced vital capacity [FEV1/FVC]), or clinical laboratory panel, unless deemed not clinically significant by the PI or the appropriately qualified designee.
  20. Subjects who have, or who have had a history of, any clinically significant neurological, gastrointestinal, renal (including urinary tract infection or nephrolithiasis), hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorder that, in the opinion of the PI or the appropriately qualified designee, would jeopardise the safety of the subject or impact on the validity of the study results.
  21. Subjects who have previously been diagnosed with any form of malignancy.
  22. Subjects who have any clinically significant abnormal laboratory safety findings at Screening and prior to first product use, as determined by the PI or the appropriately qualified designee (1 repeat assessment is acceptable).
  23. Subjects who have previously been randomised into or withdrawn from this study.
  24. Subjects who, in the opinion of the PI or the appropriately qualified designee, should not participate in this study.

Compliance with all inclusion and exclusion criteria will be reaffirmed at each study Visit.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03272295


Contacts
Layout table for location contacts
Contact: Ian M Fearon, PhD +44 (0) 2380 588641 ian_fearon@bat.com
Contact: Alison C Eldridge, HNC +44 (0) 2380 793499 alison_eldridge@bat.com

Locations
Layout table for location information
United Kingdom
Celerion Not yet recruiting
Belfast, Northern Ireland, United Kingdom, BT9 6AD
Contact: Johnston Stewart, MB    +44 (0) 28 90 554040 ext 4014    adrian.stewart@celerion.com   
Principal Investigator: Johnstone Stewart, MB         
Sponsors and Collaborators
British American Tobacco (Investments) Limited
Philip Morris Products S.A.
Imperial Tobacco Group PLC
Japan Tobacco Inc.
Korea Ginseng Corporation
Investigators
Layout table for investigator information
Principal Investigator: Johnston Stewart, MB Celerion GB Ltd

Layout table for additonal information
Responsible Party: British American Tobacco (Investments) Limited
ClinicalTrials.gov Identifier: NCT03272295     History of Changes
Other Study ID Numbers: BAT1117009
CA21208 ( Other Identifier: Celerion GB Ltd )
First Posted: September 5, 2017    Key Record Dates
Last Update Posted: September 5, 2017
Last Verified: August 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Fenugreek seed meal
Nicotine
Menthol
Glycerol
Sorbitol
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antipruritics
Dermatologic Agents
Cryoprotective Agents
Protective Agents
Cathartics
Gastrointestinal Agents
Hypoglycemic Agents